<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077021</url>
  </required_header>
  <id_info>
    <org_study_id>CBR-CCW702-3001</org_study_id>
    <nct_id>NCT04077021</nct_id>
  </id_info>
  <brief_title>First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer</brief_title>
  <official_title>A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calibr, a division of Scripps Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calibr, a division of Scripps Research</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part,
      first-in-human study to assess the safety and tolerability of CCW702 administered
      subcutaneously to patients with metastatic, castration resistant prostate cancer. In part I,
      patients will receive ascending dosages of CCW702 with the goal to determine the maximum
      tolerated dose (MTD) of CCW702. In part II of the study, patients will be given the
      recommended phase 2 dose (RP2D) evaluating two regimens of CCW702 to determine which regimen
      is most efficacious. The study will also assess the pharmacokinetics and pharmacodynamics of
      CCW702.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1, Dose escalation: to assess the safety and tolerability of increasing doses of CCW702: number of first cycle dose limiting toxicities</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Measure the number of first cycle dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2, Dose expansion: to assess clinical efficacy at the recommended phase 2 dose.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Responses will be measured using prostate cancer working group 3 (PCWG3) criteria</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Castration-Resistant Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCW702 is administered subcutaneously with ascending dose levels to determine maximal tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCW702 is administered subcutaneously at the recommended phase 2 dose (RP2D). Different dosing regimens will be compared.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCW702</intervention_name>
    <description>Investigational immunotherapy for prostate cancer</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men ≥ 18 years of age at Screening

          -  For Part 1 and Part 2: men with metastatic castration resistant prostate cancer
             (mCRPC) with histologically or cytologically confirmed adenocarcinoma of the prostate
             as defined by one or more of the Prostate Cancer Clinical Trials Working Group 3
             (PCWG3) criteria

          -  Patients with treated brain metastasis or LMD are eligible if brain imaging shows no
             evidence of progression

          -  Must have prostate-specific antigen (PSA) and/or radiographic progression on AT LEAST
             One novel androgen receptor (AR)-targeted therapy (abiraterone acetate, enzalutamide).
             One prior chemotherapy agent for mCRPC will be allowed

          -  Eastern Cooperative Oncology Group performance status of 0-1

          -  Adequate liver function

          -  Adequate hematopoietic function

          -  Testosterone level ≤ 50 ng/mL (or 1.73 nmol/L)

          -  Patient has a life expectancy of greater than 12 weeks

        Exclusion Criteria:

          -  Patients whose tumors solely exhibit neuroendocrine differentiation or small cell
             features by histopathology

          -  Patients with new or progressive brain metastasis or Leptomeningeal Disease (LMD)

          -  Patients with a history of clinically significant cardiovascular disease such as
             symptomatic congestive heart failure, uncontrolled hypertension, unstable angina
             pectoris, history of stroke or myocardial infarction within 6 months of enrollment

          -  Patients with peripheral neuropathy CTCAE Grade &gt;/= 2

          -  Patients with a known history of hypersensitivity, allergy or intolerance to CCW702 or
             its excipients

          -  Patients with untreated or imminent spinal cord compression
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Markowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University Hospital - Sidney Kimmel Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela D Garzone, Ph.D</last_name>
    <phone>858-242-1072</phone>
    <email>pgarzone@scripps.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria LaBush</last_name>
      <phone>313-576-8411</phone>
      <email>labushv@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Heath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kim CH, Axup JY, Lawson BR, Yun H, Tardif V, Choi SH, Zhou Q, Dubrovska A, Biroc SL, Marsden R, Pinstaff J, Smider VV, Schultz PG. Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17796-801. doi: 10.1073/pnas.1316026110. Epub 2013 Oct 14.</citation>
    <PMID>24127589</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

